Browsing by Author "Heydari, Hafez"
Now showing 1 - 6 of 6
Results Per Page
Sort Options
- Effect of omega-3 fatty acids supplementation on adipokines: a systematic review and meta-analysis of randomized controlled trialsPublication . Sepidarkish, Mahdi; Rezamand, Gholamreza; Qorbani, Mostafa; Heydari, Hafez; Estêvão, M. Dulce; Omran, Dalia; Morvaridzadeh, Mojgan; Roffey, Darren M.; Farsi, Farnaz; Ebrahimi, Sara; Shokri, Fatemeh; Heshmati, JavadBackground Although a large body of literature reported the beneficial effects of omega-3 fatty acids (omega-3 FAs) consumption on adipokines levels, but recent findings from clinical trials are not univocal. The aim of this systematic review and meta-analysis was to evaluate the effect of omega-3 FAs supplements on adipokines. Methods We searched Medline, Web of Science, Scopus, Embase, and Cochrane Library from inception to August 2020 without any particular language limitations. Outcomes were summarized as standardized mean difference (SMD) with 95% confidence intervals (CIs) estimated from Hedge's g and random effects modeling. Results Fifty-two trials involving 4,568 participants were included. Omega-3 FAs intake was associated with a significant increase in plasma adiponectin levels (n = 43; 3,434 participants; SMD: 0.21, 95% CI: 0.04, 0.37; p = 0.01; I-2= 80.14%). This meta-analysis indicates that supplementing participants with omega-3 fatty acids more than 2000 mg daily and more than 10 weeks resulted in a significant and more favorable improvement in plasma adiponectin levels. However, omega-3 FAs intake had no significant effect on leptin levels (SMD: -0.02, 95% CI: -0.20, 0.17, I-2= 54.13%). Conclusion The evidence supports a beneficial effect of omega-3 FAs intake on serum adiponectin levels but does not appear to impact on leptin concentrations. Larger well-designed RCTs are still required to evaluate the effect of omega-3 FAs on leptin in specific diseases.
- Effect of saffron supplementation on liver enzymes: a systematic review and meta-analysis of randomized controlled trialsPublication . Hasani, Motahareh; Malekahmadi, Mahsa; Rezamand, Gholamreza; Estêvão, M. Dulce; Pizarro, Ana Beatriz; Heydari, Hafez; Hoong, Wong Chun; Arafah, Omar Ahnaf; Barakeh, Abdul Rahman Riad; Rahman, Areej; Alrashidi, Mona Saud K.; Abu-Zaid, AhmedBackground and aims: Possible protective effects of saffron (Crocus sativus L) have been reported in several randomized clinical trials (RCTs). Current systematic review was performed to summarize the efficacy of saffron intake on liver enzymes. Methods: An electronic database search was conducted on PubMed/Medline, Scopus, Web of Science, and Cochrane for RCTs comparing effect of saffron and placebo on liver enzymes from inception to July 2021. There was no restriction in language of included studies and we calculated the standardized mean difference (SMD) and 95% Confidence Intervals (CI) for each variable. Random-effect model was used to calculate effect size. Results: Eight studies (n = 463 participants) were included in the systematic review. The saffron intake was associated with a statistically significant decrease in aspartate aminotransferase (AST) (SMD: -0.18; 95% CI: -0.34, -0.02; I-2 = 0%) in comparison to placebo intake. Our results also indicated that saffron consumption did not have a significant effect on alanine aminotransferase (ALT) (SMD: -0.14; 95% CI: -0.36, 0.09; I-2 = 47.0%) and alkaline phosphatase (ALP) levels (SMD: 0.14; 95% CI: -0.18, 0.46; I-2 = 42.9%) compared to placebo. Conclusions: Saffron intake showed beneficial impacts on circulating AST levels. However, larger well-designed RCTs are still needed to clarify the effect of saffron intake on these and other liver enzymes.
- Effect of saffron supplementation on oxidative stress parameters: A systematic review and meta‐analysis of randomized placebo‐controlled trialsPublication . Morvaridzadeh, Mojgan; Agah, Shahram; Estêvão, M. Dulce; Hosseini, Ava Sadat; Heydari, Hafez; Toupchian, Omid; Abdollahi, Shima; Persad, Emma; Abu‐Zaid, Ahmed; Rezamand, Gholamreza; Heshmati, JavadOxidative stress (OS), the absence of equilibrium between prooxidants and antioxi dants in the body, has been shown to play a pivotal role in the initiation and pro gression of many diseases. Saffron has been noted for its antioxidant capacity and can be used to improve OS parameters in unhealthy patients. Our aim was to evalu ate the efficacy of saffron supplementation on OS parameters in unhealthy patients in randomized controlled trials (RCTs). We searched Medline, EMBASE, Cochrane CENTRAL, Scopus, and Web of Science without language restrictions for RCTs up until April 2021. Studies were included if they compared any form of saffron sup plementation to placebo or no supplementation on OS parameters in unhealthy pa tients. Using a random-effects model with calculated standardized mean difference (SMD) and 95% confidence intervals (CI), we quantitatively synthesized the data. Heterogeneity was assessed using Cochrane's I 2 values. Ten randomized controlled trials were eligible for this review. Seven were included in the meta-analysis and indicated an association between saffron intake and a statistically significant decrease in malondialdehyde (MDA) levels (SMD: −0.40; 95% CI: −0.63, −0.17; I 2 = 32.6%) and a significant increase in total antioxidant capacity (TAC, SMD: 0.24; 95% CI: 0.05, 0.42; I 2 = 00.0%). Saffron intake was shown to significantly impact MDA and TAC, indicating its beneficial properties in improving OS in unhealthy patients. However, additional RCTs are required to evaluate the effect on other OS parameters.
- Effects of body weight regain on leptin levels: a systematic review and meta-analysisPublication . Rostami Rayeni, Najme; Abdollahzad, Hadi; Alibakhshi, Pooya; Morvaridzadeh, Mojgan; Heydari, Hafez; Dehnad, Afsaneh; Khorshidi, Masoud; Izadi, Azimeh; Shidfar, Farzad; Estêvão, Dulce; Omidi, Amirhosein; Heshmati, JavadBackground: There are different changes observed before and after diet therapy, and also after weight regain. However, there is not sufficient information regarding weight regain and hormonal changes. Purpose: The purpose of this study was to review the connection between weight regain and leptin concentration levels. Methods: MEDLINE, SCOPUS, Web of Science, and the Cochrane Library were searched for interventional articles published from January 1, 1980, to June 30, 2020. Randomized clinical trials with parallel or cross over design assessing leptin concentrations at the baseline and at the end of study were reviewed. Two independent reviewers extracted data related to study design, year of publication, country, age, gender, body mass index (BMI), duration of the following up period and mean +/- SD of other intended variables. Results: Four articles were included, published between 2004 and 2016. Three of them were conducted in the US and one of them in Netherland. Sample size of the studies ranged between 25 and 148 participants. The range of following up period was from13 to 48 weeks. The age range of participants was from 34 to 44 years. Our analysis shows that weight regain could reduce leptin levels, but this change is not statistically significant. Conclusion: This review suggests that weight regain may induce a non-significant reduction in leptin level. However, the limited number and great heterogeneity between the included studies may affect the presented results and there are still need to well-designed, large population studies to determine the relationship between weight regain and leptin levels.
- Sumac fruit supplementation improve glycemic parameters in patients with metabolic syndrome and related disorders: a systematic review and meta-analysisPublication . Ghafouri, Atie; Estêvão, M. Dulce; Alibakhshi, Pooya; Pizarro, Ana Beatriz; Kashani, Amirhossein Faghihi; Persad, Emma; Heydari, Hafez; Hasani, Motahareh; Heshmati, Javad; Morvaridzadeh, MojganBackground: Metabolic syndrome (MetS) is the one of the main causes of mortality worldwide. Several randomized controlled trials (RCTs) have revealed the beneficial effects of sumac (Rhus coriaria) on cardiometabolic risk factors. However, the entirety of the evidence has yet to be summarized in a systematic review. Objective: The aim of this systematic review and meta-analysis was to evaluate the effects of sumac on several cardiometabolic risk factors in patients with MetS and related disorders. Methods: We reviewed Medline, Scopus, Web of Science and Cochrane CENTRAL for RCTs published from inception to December 2020 evaluating the impact of sumac in adults with MetS or related disorders. Outcome measures included anthropometric measures, glycemic indices, blood lipids, blood pressure and liver enzymes. Pooled effect sizes were reported as standard mean differences (SMDs) and 95% confidence intervals (CIs). Trials were pooled using a random effects model. Results: Nine studies enrolling 526 participants met the inclusion criteria for this meta-analysis. Our results indicate that sumac intake significantly decrease fasting blood sugar (FBS) (SMD: 0.28; 95% CI: 0.54, -0.02; I-2 = 00.0%), insulin (SMD: 0.67; 95% CI: 0.99, -0.36; I-2 = 03.7%), and insulin resistance (measured through the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)) (SMD: 0.79; 95% CI: 1.24, -0.34; I-2 = 50.1%). Sumac intake did not have a significant impact on weight, body mass index (BMI), waist circumference (WC), hip circumference (HC), waist to hip ratio (WHR), HbA1c, total cholesterol (TC), triglycerides (TG), high density lipoproteins (HDL), low density lipoprotein (LDL), systolic blood pressure (SBP), diastolic blood pressure (DBP), aspartate transaminase (AST) and alanine transaminase (ALT). Conclusion: Sumac, as an adjuvant therapy, may decrease serum levels of FBS, insulin and HOMA-IR. However, due to high heterogeneity in the included studies, these findings must be interpreted with great caution. Larger, well-designed placebo-controlled clinical trials are still needed to further evaluate the capacity of sumac as a complementary treatment to control MetS risk factors.
- The effect of chromium intake on oxidative stress parameters: A systematic review and meta-analysisPublication . Morvaridzadeh, Mojgan; Estêvão, M. Dulce; Qorbani, Mostafa; Heydari, Hafez; Hosseini, Ava sadat; Fazelian, Siavash; Belančić, Andrej; Persad, Emma; Rezamand, Gholamreza; Heshmati, JavadBackground: Trivalent chromium is a trace element thought to have a beneficial effect on oxidative stress (OS) parameters and inflammation. This review aimed to investigate the dose-response of chromium and summarize the effects of chromium supplementation on OS parameters in the literature. Methods: MEDLINE, Scopus, Web of Science and Cochrane CENTRAL databases were searched for RCTs published from inception to January 2021 evaluating the effect of chromium supplementation on OS parameters, namely MDA, TBARS, SOD, TAS, CAT, GPx, and GSH. A random-effects model was used to pool data and calculated standard mean difference and 95 % confidence intervals. Quantified heterogeneity among studies was assessed through Cochrane’s I 2 values. Results: Nine studies enrolling 550 participants met the inclusion criteria. The obtained results indicate that chromium supplementation significantly increases TAC (SMD: 0.46; 95 % CI: 0.08, 0.84; I 2 = 00.0 % n = 2) and significantly decreases MDA levels (SMD: − 0.46; 95 % CI: − 0.86, -0.07; I 2 = 52.4 % n = 5). Supplementation did not significantly change CAT, GPx, GSH, SOD, TAS, and TBARS. Conclusion: Chromium supplementation may improve OS parameters, however, due to high heterogeneity observed in the included studies, these findings should be interpreted with caution. Large RCTs on various patient groups evaluating the impact of chromium supplementation are needed to allow an adequate generalization of the benefits of chromium on human health.